Resonance Health Ltd (ASX:RHT) Share Price

Company Profile

Business description
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group’s core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Contact
141 Burswood Road
Level 1
Burswood
PerthWA6100
AUS
T: +61 892865300
https://www.resonancehealth.com
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2026
Employees
18

Recommended

Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.

Jon Mills, CFA | 08 October 2025

Charts from the Australian Dividend Outlook show the sectors where they are abundant.

Shani Jayamanne | 08 October 2025

Investors may be too pessimistic about this industry.

Jon Mills, CFA | 07 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,276.20	20.30	-0.22%
CAC 40	8,060.13	85.28	1.07%
DAX 40	24,597.13	211.35	0.87%
Dow JONES (US)	46,601.78	1.20	-0.00%
FTSE 100	9,548.87	65.29	0.69%
HKSE	26,907.06	77.60	0.29%
NASDAQ	23,043.38	255.02	1.12%
Nikkei 225	48,435.64	700.65	1.47%
NZX 50 Index	13,570.86	2.38	0.02%
S&P 500	6,753.72	39.13	0.58%
S&P/ASX 200	8,969.40	25.60	-0.28%
SSE Composite Index	3,930.87	48.09	1.24%